Replies to Post #346 onRevance Therapeutics Inc (RVNC) | InvestorsHub

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Replies to post #346 on Revance Therapeutics Inc (RVNC)

Replies to #346 on Revance Therapeutics Inc (RVNC)

02/28/18 4:53 PM

#348 RE: DewDiligence #346

RVNC 4Q17 results—$283M cash at 12/31/17 (excludes $25M from MYL announced today):

https://finance.yahoo.com/news/revance-releases-fourth-quarter-full-211000767.html

2018 cash-usage guidance remains unchanged from prior guidance: $117-137M.

02/28/18 5:16 PM

#349 RE: DewDiligence #346

More details on RVNC/MYL Botox FoB: #msg-138921254.